Wykonanie metodą odkrywkową portali tunelu na Słowacji

Konstrukcja portali nowego tunelu Šibenik, zbudowanego metodą odkrywkową w powiecie Lewocza na Słowacji, została wykonana przy użyciu systemu prefabrykowanych elementów żelbetowych o przekroju łukowym. Na Słowacji była to pierwsza tego typu konstrukcja dla poprowadzenia autostrady. W artykule przedstawiono ogólne informacje dotyczące budowy obiektu tunelowego w ramach projektu budowy autostrady D1 Jánovce – Jablonov, a także szczegóły prac związanych z technologią wykonania tunelu. Cały projekt D1 Jánovce – Jablonov był realizowany zgodnie z żółtą książką FIDIC jako zaprojektuj i zbuduj

LightCycler®-Based Quantitative Real-time PCR Monitoring of Patients with Follicular Lymphoma Receiving Rituximab in Combination with Conventional or High-Dose Cytotoxic Chemotherapy.

Objectives: Quantitative real-time polymerase chain reaction (qPCR) is a suitable method to measure residual disease in hemato¬logical malignancies. Our objective was to assess a LightCycler based qPCR for t(14 18)(q32 q21)(6c 2) positive cells quantification in the context of clinical and morphopathological characteristics of patients with follicular lymphoma treated with rituximab (R) in combination with conventional or high-dose chemotherapy. Methods: A total of 270 bone marrow (BM) and peripheral blood (PB) samples collected from 52 patients with follicular lymphoma at diagnosis or at relapse before or sequentially during therapy were examined by qPCR and nested PCR. Results: A greater amount of t(14 18) positive cells was observed in BM in comparison with PB in 76 percent of paired samples. The presence and number of t(14 I8) positive cells in BM and PB correlated with lymphoma activity. Significantly higher numbers of lymphoma cells were found in patients under non-remission compared with patients in clinical remission. During non-remission, 10-fold higher numbers were measured at relapse than at diagnosis. During remission, significantly higher levels were found in partial compared with complete remission. During first-line therapy, R cyclophosphamide adriamycin vincristine prednisone (CHOP) had higher in vivo purging ability than R fludara bine mitoxantrone (FM). After R high-dose cytosine-arabinoside and mitoxantrone (HAM) or R carmustine etoposide cytarabine melphalan (BEAM), the level of t(14 18) positive cells dropped below the detection limit in 80 per cent of patients. Conclusions: LightCycler qPCR is a reliable method for quantitative molecular monitoring of t(14 18) positive cells in BM and PB of patients with follicular lymphoma. It reflects the clinical characteristics of patients and allows assessment of response to different treatment regimens on a molecular level.JRC.E.5-Nuclear chemistr

The influence of the pituitary tumor transforming gene-1 (PTTG-1) on survival of patients with small cell lung cancer and non-small cell lung cancer

<p>Abstract</p> <p>Background</p> <p>PTTG-1 (pituitary tumor transforming gene) is a novel oncogene that is overexpressed in tumors, such as pituitary adenoma, breast and gastrointestinal cancers as well as in leukemia. In this study, we examined the role of PTTG-1 expression in lung cancer with regard to histological subtype, the correlation of PTTG-1 to clinical parameters and relation on patients' survival.</p> <p>Methods</p> <p>Expression of PTTG-1 was examined immunohistochemically on formalin-fixed, paraffin-embedded tissue sections of 136 patients with small cell lung cancer (SCLC) and 91 patients with non-small cell lung cancer (NSCLC), retrospectively. The intensity of PTTG-1 expression as well as the proportion of PTTG-1 positive cells within a tumor was used for univariate and multivariate analysis.</p> <p>Results</p> <p>PTTG-1 expression was observed in 64% of SCLC tumors and in 97.8% of NSCLC tumors. In patients with SCLC, negative or low PTTG-1 expression was associated with a shorter mean survival time compared with patients with strong PTTG-1 expression (265 ± 18 days vs. 379 ± 66 days; p = 0.0291). Using the Cox regression model for multivariate analysis, PTTG-1 expression was a significant predictor for survival next to performance status, tumor stage, LDH and hemoglobin.</p> <p>In contrast, in patients with NSCLC an inverse correlation between survival and PTTG-1 expression was seen. Strong PTTG-1 expression was associated with a shorter mean survival of 306 ± 58 days compared with 463 ± 55 days for those patients with no or low PTTG-1 intensities (p = 0.0386). Further, PTTG-1 expression was associated with a more aggressive NSCLC phenotype with an advanced pathological stage, extensive lymph node metastases, distant metastases and increased LDH level. Multivariate analysis using Cox regression confirmed the prognostic relevance of PTTG-1 expression next to performance status and tumor stage in patients with NSCLC.</p> <p>Conclusion</p> <p>Lung cancers belong to the group of tumors expressing PTTG-1. Dependent on the histological subtype of lung cancer, PTTG-1 expression was associated with a better outcome in patients with SCLC and a rather unfavourable outcome for patients with NSCLCs. These results may reflect the varying role of PTTG-1 in the pathophysiology of the different histological subtypes of lung cancer.</p